hYAK3 polypeptides and polynucleotides and methods for producing such polype ptides by recombinant techniques are disclosed. Also disclosed are methods for util izing hYAK3 polypeptides and polynucleotides in the design of protocols for the treatmen t of bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Dise ase Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IB D), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozo an and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia an d other immunodeficiency disorders; septic shock; pain; injury; cancers including te sticular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including res tenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urina ry retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurologic al disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome. , among others, and diagnostic assays for such conditions.
HUMAN PROTEIN KINASES HYAK3